Japan approves Regeneron, Sanofi’s Dupixent for pediatric asthma
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) received marketing authorization in Japan for their blockbuster drug Dupixent to treat severe asthma in children aged 6 to 11.


-640x358.jpg&w=3840&q=75)




-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)